Overview
Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling
Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occurring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.
Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occurring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.
Current Appointments & Affiliations
Professor of Medicine
·
2016 - Present
Medicine, Hematology,
Medicine
Member of the Duke Cancer Institute
·
2012 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
Journal Article Clin Adv Hematol Oncol · March 2024 The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxol ... Link to item CiteUpfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Journal Article Bone Marrow Transplant · February 2024 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAK ... Full text Link to item CiteCorrection: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Journal Article Bone Marrow Transplant · February 2024 Full text Link to item CiteRecent Grants
A phase 1b Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF).
Clinical TrialPrincipal Investigator · Awarded by Samus Therapeutics, Inc. · 2018 - 2021A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2017 - 2020A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2016 - 2019View All Grants
Education, Training & Certifications
Aegean University, School of Medicine (Turkey) ·
1987
M.D.